{"disease":{"id":"idiopathic-multicentric-castleman-39-s-disease","name":"idiopathic multicentric castleman 39 s disease"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05345522","title":"A Study of Anti-IL-6R mAb Injection in Patients With iMCD","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":25,"lead_sponsor_name":"Beijing VDJBio Co., LTD.","has_results":false},{"nct_id":"NCT07085039","title":"Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":14,"lead_sponsor_name":"University of Pennsylvania","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}